CN113755380A - Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method - Google Patents
Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method Download PDFInfo
- Publication number
- CN113755380A CN113755380A CN202111114577.1A CN202111114577A CN113755380A CN 113755380 A CN113755380 A CN 113755380A CN 202111114577 A CN202111114577 A CN 202111114577A CN 113755380 A CN113755380 A CN 113755380A
- Authority
- CN
- China
- Prior art keywords
- solution
- culture medium
- strain
- diphtheria toxin
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 51
- 108010053187 Diphtheria Toxin Proteins 0.000 title claims abstract description 34
- 238000000855 fermentation Methods 0.000 title claims abstract description 23
- 230000004151 fermentation Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000011084 recovery Methods 0.000 title claims abstract description 15
- 238000012136 culture method Methods 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 41
- 239000007788 liquid Substances 0.000 claims abstract description 38
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims abstract description 34
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 22
- 102000016607 Diphtheria Toxin Human genes 0.000 claims abstract description 19
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 15
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 140
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 22
- 239000001110 calcium chloride Substances 0.000 claims description 22
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 22
- 229940041514 candida albicans extract Drugs 0.000 claims description 20
- 239000008215 water for injection Substances 0.000 claims description 20
- 239000012138 yeast extract Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 19
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 14
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 13
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 9
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 9
- 239000004158 L-cystine Substances 0.000 claims description 9
- 235000019393 L-cystine Nutrition 0.000 claims description 9
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 229940000635 beta-alanine Drugs 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 229960003067 cystine Drugs 0.000 claims description 9
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 9
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 9
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 7
- 238000007790 scraping Methods 0.000 claims description 7
- LOCHUGHDBWUEDN-UHFFFAOYSA-L zinc;sulfate;pentahydrate Chemical compound O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O LOCHUGHDBWUEDN-UHFFFAOYSA-L 0.000 claims description 7
- 239000005018 casein Substances 0.000 claims description 6
- -1 casein amino acid Chemical class 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000011218 seed culture Methods 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000012262 fermentative production Methods 0.000 claims 6
- 239000002609 medium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 description 31
- 238000004108 freeze drying Methods 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 238000000859 sublimation Methods 0.000 description 5
- 230000008022 sublimation Effects 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000033 toxigenic Toxicity 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012879 subculture medium Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application relates to the field of bioengineering, in particular to a strain culture medium for producing diphtheria toxin non-toxic CRM197 protein by fermentation, a preparation method and a strain recovery culture method; a strain culture medium for producing diphtheria toxin non-toxic CRM197 protein by fermentation is prepared from solution A, solution B, solution C and solution D; the preparation method of the strain culture medium comprises the following steps: s1, preparing a solution; s1.1, preparing a solution A; s1.2, preparing a solution B; s1.3, preparing a solution C; s1.4, preparing a solution D; and S2, mixing the solution. The strain recovery culture method comprises the following steps: step one, re-dissolving strains; step two, first generation solid culture; step three, second generation solid culture; and step four, collecting bacterial liquid. The present application can construct CRM197 master seed library or working seed library with higher activity.
Description
Technical Field
The application relates to the field of bioengineering, in particular to a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation, a preparation method and a strain recovery culture method.
Background
CRM197 is a non-toxic form of diphtheria toxin but it is not immunologically distinct from diphtheria toxin. CRM197 is produced by Corynebacterium diphtheriae infected with the non-toxigenic phage β 197tox, whereas β 197tox was created by nitrosoguanidine mutagenesis of toxigenic coryneform bacteria (Uchida et al Nature New Biology (1971) 233; 8-11). The CRM197 protein has the same molecular weight as diphtheria toxin but differs in its structural gene by a single base change. This results in a change of the amino acid at position 52 from glycine to glutamine, rendering the A-fragment unable to bind NAD and therefore non-toxic (Pappenheimer 1977, AnnRev, biochem.46; 69-94, Rappuooliapplied and Environmental Microbiology Sept 1983p 560-564). CRM197 protein without toxicity can still be combined with receptors of sensitive cells, namely CRM197 protein loses enzyme activity and toxicity and retains the immunogenicity of diphtheria toxin, so that the CRM197 protein is an ideal carrier protein of polysaccharide conjugate vaccines.
However, whether the CRM197 strain is natural or the CRM197 engineering strain is constructed by recombination, in the actual strain fermentation process, a culture medium and a culture mode are important rings for limiting the high yield of the CRM197 engineering strain. Therefore, the development of a proper culture medium and culture mode, and the construction of a CRM197 main seed bank or a working seed bank with higher activity is an urgent problem to be solved.
Disclosure of Invention
In order to obtain zymocyte liquid with high expression quantity and construct a CRM197 main seed library or a working seed library with higher activity, the application provides a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation, a preparation method and a strain recovery culture method.
In a first aspect, the present application provides a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation, which adopts the following technical scheme:
a strain culture medium for producing diphtheria toxin CRM197 protein through fermentation comprises a culture medium and a culture medium, wherein the culture medium comprises the following components in volume ratio of (1000): (2-6): (1-5): (24-42) solution A, solution B, solution C, and solution D;
every 1000mL of the solution A is prepared from the following raw materials: 20-32g of yeast extract, 7-13g of casein amino acid, 47-58mg of L-tryptophan, 3-8g of monopotassium phosphate and 1-2g of calcium chloride;
every 100mL of the solution B is prepared from the following raw materials: 20-24g of magnesium sulfate heptahydrate, 130mg of beta-alanine 110-;
every 100mL of the solution C is prepared from the following raw materials: 15-23g of L-cystine and 11-24ml of hydrochloric acid;
every 100mL of the solution D is prepared from the following raw materials: 30-55g of maltose and 0.5-2g of calcium chloride.
By adopting the technical scheme, firstly, in the formula of the strain culture medium, except yeast extract and casamino acid, other components are domestic reagents, so that the production cost is greatly reduced.
Secondly, through the formula of the culture medium of the CRM197 strain, the CRM197 strain can be amplified in a large scale to obtain a zymogen liquid with high expression, so that a CRM197 main seed library or a working seed library with higher activity is constructed.
Preferably, the culture medium consists of a mixture comprising by volume (1000): (2): (1): (30) solution A, solution B, solution C and solution D.
Preferably, each 1000mL of the solution A is prepared from the following raw materials: 20g of yeast extract, 10g of casein amino acid, 50mg of L-tryptophan, 5g of monopotassium phosphate and 1g of calcium chloride;
every 100mL of the solution B is prepared from the following raw materials: 22.5g of magnesium sulfate heptahydrate, 115mg of beta-alanine, 115mg of nicotinic acid, 7.5mg of pimelic acid, 0.5g of copper sulfate pentahydrate, 0.2g of zinc sulfate pentahydrate, 75mg of manganese sulfate tetrahydrate and 3mL of hydrochloric acid; every 100mL of the solution C is prepared from the following raw materials: 20g of L-cystine and 20ml of hydrochloric acid;
every 100mL of the solution D is prepared from the following raw materials: maltose 50g, calcium chloride 0.5 g.
Preferably, the solution A, the solution B, the solution C and the solution D are all prepared by adopting water for injection at 50-60 ℃.
The injection water is double distilled water after sterilization, so that the risk of the culture medium being infected by mixed bacteria is effectively reduced; in addition, the water for injection at 50 ℃ to 60 ℃ is preferable because it can effectively promote the rapid dissolution of each component and ensure the effectiveness of each component so that it is in an equilibrium state.
In a second aspect, the present application provides a preparation method of a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation, which adopts the following technical scheme:
a preparation method of a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation comprises the following steps:
s1 preparation solution
S1.1, preparing solution A
Mixing yeast extract, casamino acid, L-tryptophan, potassium dihydrogen phosphate and calcium chloride with water for injection, dissolving, and metering to 1000ml to obtain solution A.
S1.2, preparing solution B
Fully mixing and dissolving magnesium sulfate heptahydrate, beta-alanine, nicotinic acid, pimelic acid, copper sulfate pentahydrate, zinc sulfate pentahydrate, manganese sulfate tetrahydrate and hydrochloric acid by using water for injection, and then fixing the volume to 100ml to obtain a solution B;
s1.3, preparing solution C
Fully mixing and dissolving L-cystine and hydrochloric acid with water, and then fixing the volume to 100ml to obtain a solution C;
s1.4, preparing solution D
Fully mixing and dissolving maltose and calcium chloride with water for injection, and then fixing the volume to 100ml to obtain a solution D;
s2, mixing the solution
Adding the solution B and the solution C into the solution A according to the proportion, and sterilizing; and cooling, adding the solution D, adding agar powder, sterilizing and subpackaging to obtain the strain culture medium.
Preferably, S1.1, preparing the solution A, fully mixing and dissolving the yeast extract, the casamino acid, the L-tryptophan, the potassium dihydrogen phosphate and the calcium chloride with water for injection, adjusting the pH value to 7.4 +/-0.2, and then fixing the volume to 1000ml to obtain the solution A.
Preferably, S1.1, preparing solution A, fully mixing and dissolving the yeast extract, the casamino acid, the L-tryptophan, the potassium dihydrogen phosphate and the calcium chloride with water for injection, adjusting the pH value to 7.4 +/-0.2, fixing the volume to 1000ml, and clarifying and filtering by adopting a 0.45um filter membrane to obtain solution A.
In a third aspect, the application provides a strain recovery culture method for producing diphtheria toxin non-toxic CRM197 protein by fermentation, which adopts the following technical scheme:
a strain recovery culture method for producing diphtheria toxin non-toxic CRM197 protein by fermentation comprises the following steps:
step one, re-dissolving strains
Starting a strain for producing diphtheria toxin non-toxic CRM197 protein through fermentation, and repeatedly blowing and beating until the diphtheria toxin non-toxic CRM197 protein is completely dissolved to obtain re-dissolved bacteria liquid;
step two, first generation solid culture
Inoculating the re-dissolved bacterial liquid into the culture medium to serve as a first generation solid culture medium, and culturing for 4-24h in an incubator at 28-38 ℃;
step three, second generation solid culture
Scraping colony on the surface of the first generation solid culture medium with strain rod, spreading on the culture medium of any one of claims 1-5, culturing as second generation solid, placing in incubator at 28-38 deg.C, and culturing for 4-24 h;
step four, collecting bacteria liquid
Scraping and washing the bacterial colony on the surface of the second-generation solid culture medium, and then sucking the bacterial liquid and transferring the bacterial liquid to an aseptic bottle to obtain the bacterial liquid.
Preferably, in the step one, the solution for dissolving the original strain is solution E, and the preparation method of the solution E comprises the following steps: mixing yeast extract 0-100g with injectable water, dissolving, and diluting to 100 ml.
Preferably, step four, scraping and washing the surface bacterial colonies of the second-generation solid culture medium by using a solution F, and then sucking a bacterial liquid and transferring the bacterial liquid to an aseptic bottle to obtain a bacterial liquid; the preparation method of the solution F comprises the following steps: fully mixing and dissolving 5-50g of trehalose with water for injection, then fixing the volume to 100ml, and then sterilizing and filtering through a 0.22um filter membrane.
In summary, the present application has the following beneficial effects:
1. constructing a CRM197 main seed library or a working seed library with higher activity;
2. the related reagents of the subculture medium except yeast extract and casamino acid are made in China, so that the cost is low;
3. a rapid, convenient and efficient fermentation culture amplification mode.
Detailed Description
The strain source is as follows: the strain was purchased from the American type culture Collection with the strain number ATCC39255 or ATCC39526 or ATCC11049 or ATCC51926 or ATCC 51280.
Each 1000mL of solution A was prepared from the following raw materials, as shown in Table 1.
Table 1 solution a formula table
| Name of reagent | Manufacturer of the product | Example 1 |
| Yeast extract | OXOID | 20g |
| Casein amino acid | OXOID | 10g |
| L-tryptophan | Chinese medicine | 50mg |
| Potassium dihydrogen phosphate | Chinese medicine | 5g |
| Calcium chloride | Chinese medicine | 1g |
Each 100mL of solution B was prepared from the following raw materials, as shown in Table 2.
Table 2 solution B formula table
| Reagent | Manufacturer of the product | Example 1 |
| Magnesium sulfate heptahydrate | Chinese medicine | 22.5g |
| Beta-alanine | Chinese medicine | 115mg |
| Nicotinic acid | Chinese medicine | 115mg |
| Pimelic acid | Chinese medicine | 7.5mg |
| Blue vitriod | Chinese medicine | 0.5g |
| Zinc sulfate pentahydrate | Chinese medicine | 0.2g |
| Manganese sulfate tetrahydrate | Chinese medicine | 75mg |
| Hydrochloric acid | Chinese medicine | 3mL |
Each 100mL of solution C was prepared from the following raw materials, as shown in Table 3.
Table 3 solution C formula table
| Name of reagent | Manufacturer of the product | Example 1 |
| L-cystine | Chinese medicine | 20g |
| Hydrochloric acid | Chinese medicine | 20ml |
Each 100mL of solution D was prepared from the following starting materials, as shown in Table 4.
Table 4 solution D formulation table
| Name of reagent | Manufacturer of the product | Example 1 |
| Maltose | Chinese medicine | 50g |
| Calcium chloride | Chinese medicine | 0.5g |
Each 100mL of solution E was prepared from the following starting materials, as shown in Table 5.
Table 5 solution E formula table
| Name of reagent | Manufacturer of the product | Example 1 |
| Yeast extract | OXOID | 10g |
Each 100mL of solution F was prepared from the following starting materials, as shown in Table 6.
Table 6 solution F formula table
| Name of reagent | Manufacturer of the product | Example 1 |
| Trehalose | OXOID | 15g |
Examples
Example 1
A preparation method of a strain culture medium for producing diphtheria toxin CRM197 protein by fermentation comprises the following steps:
s1 preparation solution
S1.1, preparing solution A
According to the formula, the yeast extract, the casamino acid, the L-tryptophan, the monopotassium phosphate and the calcium chloride are fully mixed and dissolved by using water for injection, and then the volume is determined to 1000ml, so that a solution A is obtained.
S1.2, preparing solution B
Magnesium sulfate heptahydrate, beta-alanine, nicotinic acid, pimelic acid, copper sulfate pentahydrate, zinc sulfate pentahydrate, manganese sulfate tetrahydrate and hydrochloric acid are fully mixed and dissolved by using water for injection according to a formula, and then the volume is determined to be 100ml, so that a solution B is obtained;
s1.3, preparing solution C
Fully mixing and dissolving L-cystine and hydrochloric acid by using water for injection according to a formula, and then fixing the volume to 100ml to obtain a solution C;
s1.4, preparing solution D
Fully mixing and dissolving maltose and calcium chloride by using water for injection according to a formula, and then fixing the volume to 100ml to obtain a solution D;
s2, mixing the solution
Adding 2ml of solution B and 1ml of solution C into 1000ml of solution A, and sterilizing; after cooling, 30ml of solution D was added, i.e. the volume ratio of solution a, solution B, solution C, solution D was 1000: 2:1:30, then adding agar powder according to the proportion of 1 wt%, sterilizing for 10min at 115 ℃, cooling to 50-60 ℃, subpackaging into sterile Kirschner bottles by 100 ml/bottle, spreading for complete solidification, and storing in a refrigerator at 2-8 ℃ for later use.
A strain recovery culture method for producing diphtheria toxin non-toxic CRM197 protein by fermentation comprises the following steps:
step one, re-dissolving strains
Starting a strain for producing diphtheria toxin non-toxic CRM197 protein through fermentation, adding 1ml of solution E, and repeatedly blowing and beating until the diphtheria toxin non-toxic CRM197 protein is completely dissolved to obtain re-dissolved bacteria liquid; the preparation method of the solution E comprises the following steps: fully mixing and dissolving 10g of yeast extract by using water for injection, and then fixing the volume to 100 ml;
step two, first generation solid culture
Inoculating the re-dissolved bacterial liquid into the culture medium to serve as a first generation solid culture medium, and culturing for 4-24h in an incubator at 28-38 ℃;
step three, second generation solid culture
Scraping colony on the surface of the first generation solid culture medium with strain rod, coating on the culture medium, culturing as second generation solid, and culturing at 28-38 deg.C for 8-12 hr;
step four, collecting bacteria liquid
Scraping the surface bacterial colony of the second-generation solid culture medium by using 20ml of solution F, and then sucking the bacterial liquid and transferring the bacterial liquid to an aseptic bottle to obtain bacterial liquid;
the preparation method of the solution F comprises the following steps: mixing trehalose 15.0g with injectable water, dissolving, diluting to 100ml, sterilizing with 0.22um filter membrane, and filtering.
Example 2
The difference from example 1 is that the volume ratio of solution A, solution B, solution C and solution D is 1000: 4: 3: 24.
example 3
The difference from example 1 is that the volume ratio of solution A, solution B, solution C and solution D is 1000: 6: 5: 42.
examples 4 to 5
The difference from example 1 is that the formulation of solution A is different, see Table 7.
Table 7 solution a formula table
| Name of reagent | Manufacturer of the product | Example 1 | Example 4 | Example 5 |
| Yeast extract | OXOID | 20g | 32g | 28g |
| Casein amino acid | OXOID | 10g | 7g | 13g |
| L-tryptophan | Chinese medicine | 50mg | 47mg | 58mg |
| Potassium dihydrogen phosphate | Chinese medicine | 5g | 8g | 3g |
| Calcium chloride | Chinese medicine | 1g | 2g | 1g |
Examples 6 to 7
The difference from example 1 is the formulation of solution B. See table 8 for details.
Table 8 formula of solution B
| Reagent | Manufacturer of the product | Example 1 | Example 6 | Example 7 |
| Magnesium sulfate heptahydrate | Chinese medicine | 22.5g | 20g | 24g |
| Beta-alanine | Chinese medicine | 115mg | 130mg | 110mg |
| Nicotinic acid | Chinese medicine | 115mg | 107mg | 120mg |
| Pimelic acid | Chinese medicine | 7.5mg | 6.5mg | 10.5mg |
| Blue vitriod | Chinese medicine | 0.3g | 0.5g | 1g |
| Zinc sulfate pentahydrate | Chinese medicine | 0.2g | 0.1g | 0.6g |
| Manganese sulfate tetrahydrate | Chinese medicine | 55mg | 75mg | 90mg |
| Hydrochloric acid | Chinese medicine | 3mL | 2mL | 4mL |
Examples 8 to 9
The difference from example 1 is the formulation of solution C. See table 9 for details.
Table 9 formula of solution C
| Name of reagent | Manufacturer of the product | Example 1 | Example 8 | Example 9 |
| L-cystine | Chinese medicine | 20g | 23g | 15g |
| Hydrochloric acid | Chinese medicine | 11ml | 20ml | 24ml |
Examples 10 to 11
The difference from example 1 is the formulation of solution D. See table 10 for details.
Table 10 formulation of solution D
| Name of reagent | Manufacturer of the product | Example 1 | Example 10 | Example 11 |
| Maltose | Chinese medicine | 50g | 30g | 55g |
| Calcium chloride | Chinese medicine | 0.5g | 2ml | 1ml |
Examples 12 to 13
The difference from example 1 is the formulation of solution E. See table 10 for details.
TABLE 11 formulation Table for solution E
| Name of reagent | Manufacturer of the product | Example 1 | Example 10 | Example 11 |
| Yeast extract | OXOID | 10g | 0g | 100g |
Examples 14 to 15
The difference from example 1 is the formulation of solution F. See table 10 for details.
TABLE 12 solutionsFormula table of F
| Name of reagent | Manufacturer of the product | Example 1 | Example 14 | Example 15 |
| Trehalose | Chinese medicine | 15g | 5g | 50g |
Comparative example
Comparative example 1
The difference from example 1 is that solution C is not included in the seed culture medium.
Comparative example 2
The difference from example 1 is that solution D is not included in the seed culture medium.
Performance test
Seed bacteria liquid activity test
Bacterial liquid activity tests were performed on examples 1 to 15 and comparative examples 1 to 2 by referring to the viable bacteria counting method described in "chinese pharmacopoeia" of 2015 edition, and bacterial liquid bacterial concentration cfu/ml was recorded, and the test results are shown in table 13.
TABLE 13 seed bacterial liquid activity test results table
Second, Freeze drying test
The bacterial solution obtained in example 3 was diluted to 1.0X 105、5.0×105、1.0×106、5.0×106、1.0×107、 5.0×107、1.0×108、5.0×108、1.0×109、5.0×109；
The bacterial liquid obtained in comparative example 1 was sequentially diluted to 1.0X 105、5.0×105、1.0×106、5.0×106、1.0×107、5.0 ×107；
The bacterial liquid obtained in comparative example 2 was sequentially diluted to 1.0X 105、5.0×105、1.0×106、5.0×106、1.0×107、5.0 ×107。
Freeze-drying the diluted bacterial liquid to form a CRM197 main seed library or a working seed library, and checking the bacterial concentration (cfu/ml) after freeze-drying; freeze-drying survival rate (%); resuscitating the seed bank for 1h (cfu/ml); resuscitating the seed bank for 2h concentration (cfu/ml); resuscitating the seed bank for 4h (cfu/ml); the seed bank is recovered for 4h logarithmic growth rate, and the bacterial concentration test refers to a viable bacteria counting method recorded in 'Chinese pharmacopoeia' 2015 edition.
The freeze-drying method of the bacterial liquid comprises the following steps:
s1, pre-freezing
The bacterial liquid containing the freeze-drying protective agent is prepared according to the ratio of 0.5mL/cm2Spreading in a freeze-drying stainless steel plate, and placing the freeze-drying stainless steel plate on a vacuum freeze-drying partition plate, wherein the pre-freezing conditions are as follows: the temperature of the cold trap is less than or equal to minus 40 ℃, the pre-freezing temperature is minus 40 ℃, and the temperature is maintained for 10 hours under normal pressure.
S2, sublimation drying
S2.1 first order sublimation
The freeze-drying stainless steel plate is still arranged on a clapboard of the vacuum freeze-drying machine, and the first-order sublimation condition is as follows: the temperature of the cold trap is less than or equal to minus 40 ℃, the vacuum degree is 20pa, the heating rate is 2 ℃/min, the temperature is increased to minus 30 ℃, and the temperature is maintained for 10 hours.
S2.2, second order sublimation
The freeze-drying stainless steel plate is still arranged on a clapboard of the vacuum freeze-drying machine, and the second-order sublimation condition is as follows: the temperature of the cold trap is less than or equal to minus 80 ℃, the vacuum degree is 10pa, the heating rate is 0.2 ℃/min, the temperature is increased to 0 ℃, and the temperature is maintained for 5 hours.
S3, analysis and drying
The freeze-drying stainless steel plate is still arranged on a clapboard of a vacuum freeze-drying machine, and the analysis and drying conditions are as follows: the temperature of the cold trap is less than or equal to minus 40 ℃, the vacuum degree is 10pa, the heating rate is 2 ℃/min, the temperature is increased to 28 ℃, and the temperature is maintained for 8 hours, so that the CRM197 strain freeze-dried powder is prepared.
Table 12 table of test results of diluted bacterial suspension of example 3
Table 13 table of test results of diluted bacterial liquid of comparative example 1
TABLE 14 test results of diluted bacteria solution of comparative example 2
As can be seen from examples 1-15 and comparative examples 1-2, the bacterial culture medium of the present application can greatly increase the concentration of CRM197 bacterial liquid.
From the viewpoint of the survival rate of the strain after freeze-drying, the concentration of the bacteria is controlled to be 1 × 106cfu/ml-5×109The bacterial survival rate level of freeze-drying is higher than 52% when freeze-drying is carried out between cfu/ml, which is a more suitable bacterial liquid concentration range before freeze-drying.
From the growth level of 4h of seed bank recovery, the bacteria concentration is controlled at 1X 10 if the specific growth rate increase is more than 0.26cfu/ml～1×109Freeze-drying is carried out between cfu/ml, and the recovery level of the seed bank after freeze-drying is ideal.
Controlling the bacterial concentration at 5X 10 if the specific growth rate increase is more than 0.36cfu/ml～1× 108Freeze-drying is carried out between cfu/ml, and the recovery level of the seed bank after freeze-drying is optimal.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (10)
1. A strain culture medium for producing diphtheria toxin CRM197 protein through fermentation is characterized by comprising a culture medium prepared from the following components in percentage by volume (1000): (2-6): (1-5): (24-42) solution A, solution B, solution C, and solution D;
every 1000mL of the solution A is prepared from the following raw materials: 20-32g of yeast extract, 7-13g of casein amino acid, 47-58mg of L-tryptophan, 3-8g of monopotassium phosphate and 1-2g of calcium chloride;
every 100mL of the solution B is prepared from the following raw materials: 20-24g of magnesium sulfate heptahydrate, 130mg of beta-alanine 110-;
every 100mL of the solution C is prepared from the following raw materials: 15-23g of L-cystine and 11-24ml of hydrochloric acid;
every 100mL of the solution D is prepared from the following raw materials: 30-55g of maltose and 0.5-2g of calcium chloride.
2. A seed culture medium for fermentative production of diphtheria toxin CRM197 according to claim 1, comprising a mixture of (1000): (2): (1): (30) solution A, solution B, solution C and solution D.
3. A seed culture medium for the fermentative production of diphtheria toxin CRM197 according to claim 1, wherein each 1000mL of said solution a is prepared from the following raw materials: 20g of yeast extract, 10g of casein amino acid, 50mg of L-tryptophan, 5g of monopotassium phosphate and 1g of calcium chloride;
every 100mL of the solution B is prepared from the following raw materials: 22.5g of magnesium sulfate heptahydrate, 115mg of beta-alanine, 115mg of nicotinic acid, 7.5mg of pimelic acid, 0.5g of copper sulfate pentahydrate, 0.2g of zinc sulfate pentahydrate, 75mg of manganese sulfate tetrahydrate and 3mL of hydrochloric acid;
every 100mL of the solution C is prepared from the following raw materials: 20g of L-cystine and 20ml of hydrochloric acid;
every 100mL of the solution D is prepared from the following raw materials: maltose 50g, calcium chloride 0.5 g.
4. The strain culture medium for the fermentative production of diphtheria toxin CRM197 protein according to claim 1, wherein the solutions A, B, C and D are prepared by using water for injection at 50-60 ℃.
5. A process for the preparation of a culture medium for a strain producing diphtheria toxin CRM197 protein by fermentation according to any one of claims 1 to 4, comprising the steps of:
s1 preparation solution
S1.1, preparing solution A
Sufficiently mixing and dissolving the yeast extract, the casamino acid, the L-tryptophan, the monopotassium phosphate and the calcium chloride with water for injection, and then fixing the volume to 1000ml to obtain a solution A;
s1.2, preparing solution B
Fully mixing and dissolving magnesium sulfate heptahydrate, beta-alanine, nicotinic acid, pimelic acid, copper sulfate pentahydrate, zinc sulfate pentahydrate, manganese sulfate tetrahydrate and hydrochloric acid by using water for injection, and then fixing the volume to 100ml to obtain a solution B;
s1.3, preparing solution C
Fully mixing and dissolving L-cystine and hydrochloric acid with water, and then fixing the volume to 100ml to obtain a solution C;
s1.4, preparing solution D
Fully mixing and dissolving maltose and calcium chloride with water for injection, and then fixing the volume to 100ml to obtain a solution D;
s2, mixing the solution
Adding the solution B and the solution C into the solution A according to the proportion, and sterilizing; and cooling, adding the solution D, adding agar powder, sterilizing and subpackaging to obtain the strain culture medium.
6. The method for preparing a culture medium for fermentation production of diphtheria toxin CRM197 protein according to claim 5, wherein S1.1, in the preparation of solution A, yeast extract, casamino acid, L-tryptophan, potassium dihydrogen phosphate and calcium chloride are dissolved in water for injection, the pH is adjusted to 7.4 +/-0.2, and the volume is adjusted to 1000ml to obtain solution A.
7. The method for preparing a culture medium for fermentation production of diphtheria toxin CRM197 protein according to claim 6, wherein S1.1, preparing solution A, mixing yeast extract, casamino acid, L-tryptophan, potassium dihydrogen phosphate and calcium chloride with water for injection, dissolving, adjusting pH to 7.4 + -0.2, diluting to 1000ml, clarifying with 0.45um filter membrane, and filtering to obtain solution A.
8. A strain recovery culture method using the strain culture medium for the fermentative production of diphtheria toxin CRM197 protein according to any one of claims 1 to 4, comprising the steps of:
step one, re-dissolving strains
Starting a strain for producing diphtheria toxin non-toxic CRM197 protein through fermentation, and repeatedly blowing and beating until the diphtheria toxin non-toxic CRM197 protein is completely dissolved to obtain re-dissolved bacteria liquid;
step two, first generation solid culture
Inoculating the re-dissolved bacteria liquid into the culture medium of any one of claims 1-5 to serve as a first generation solid culture medium, and culturing for 4-24h at 28-38 ℃ in an incubator;
step three, second generation solid culture
Scraping colony on the surface of the first generation solid culture medium with strain rod, spreading on the culture medium of any one of claims 1-5, culturing as second generation solid, placing in incubator at 28-38 deg.C, and culturing for 4-24 h;
step four, collecting bacteria liquid
Scraping and washing the bacterial colony on the surface of the second-generation solid culture medium, and then sucking the bacterial liquid and transferring the bacterial liquid to an aseptic bottle to obtain the bacterial liquid.
9. The strain recovery culture method for the fermentative production of diphtheria toxin non-toxic CRM197 protein according to claim 1, wherein in the step one, the solution for dissolving the original strain is solution E, and the preparation method of the solution E comprises: mixing yeast extract 0-100g with injectable water, dissolving, and diluting to 100 ml.
10. The strain recovery culture method for the fermentative production of diphtheria toxin non-toxic CRM197 protein according to claim 1, wherein in step four, the surface bacterial colony of the second-generation solid medium is scraped by using solution F, and then the bacterial liquid is sucked and transferred to a sterile bottle to obtain the bacterial liquid; the preparation method of the solution F comprises the following steps: fully mixing and dissolving 5-50g of trehalose with water for injection, then fixing the volume to 100ml, and then sterilizing and filtering through a 0.22um filter membrane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111114577.1A CN113755380A (en) | 2021-09-23 | 2021-09-23 | Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111114577.1A CN113755380A (en) | 2021-09-23 | 2021-09-23 | Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113755380A true CN113755380A (en) | 2021-12-07 |
Family
ID=78796994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111114577.1A Pending CN113755380A (en) | 2021-09-23 | 2021-09-23 | Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113755380A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113930356A (en) * | 2021-09-23 | 2022-01-14 | 艾美卫信生物药业（浙江）有限公司 | Freeze-drying method for fermentation production of diphtheria toxin non-toxic CRM197 protein strain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925792A (en) * | 1983-02-08 | 1990-05-15 | Sclavo, S.P.A. | Process for producing proteins correlated with the diphtheric toxin |
| US6689871B1 (en) * | 1999-02-26 | 2004-02-10 | Amersham Health As | Process for production diphtheria toxin |
| CN1915424A (en) * | 1995-05-04 | 2007-02-21 | 康诺特实验室有限公司 | Acellular pertussis vaccines and methods of preparation thereof |
| CN110741013A (en) * | 2017-04-22 | 2020-01-31 | 生物E有限公司 | Improved process for high level production of CRM |
-
2021
- 2021-09-23 CN CN202111114577.1A patent/CN113755380A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925792A (en) * | 1983-02-08 | 1990-05-15 | Sclavo, S.P.A. | Process for producing proteins correlated with the diphtheric toxin |
| CN1915424A (en) * | 1995-05-04 | 2007-02-21 | 康诺特实验室有限公司 | Acellular pertussis vaccines and methods of preparation thereof |
| US6689871B1 (en) * | 1999-02-26 | 2004-02-10 | Amersham Health As | Process for production diphtheria toxin |
| CN110741013A (en) * | 2017-04-22 | 2020-01-31 | 生物E有限公司 | Improved process for high level production of CRM |
Non-Patent Citations (1)
| Title |
|---|
| R. FASS等: "High-yield production of diphtheria toxin mutants by high-density culture of C7(β)tox+ strains grown in a non-deferrated medium" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113930356A (en) * | 2021-09-23 | 2022-01-14 | 艾美卫信生物药业（浙江）有限公司 | Freeze-drying method for fermentation production of diphtheria toxin non-toxic CRM197 protein strain |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105886431B (en) | The method of one plant of corynebacterium glutamicum and its high yield isoleucine | |
| US10757946B2 (en) | Microbial inoculant formulations | |
| CN102660461B (en) | Microbial preparation for shortening tobacco fermentation period and application of microbial preparation | |
| US7399615B2 (en) | Animal component free meningococcal polysaccharide fermentation and seedbank development | |
| CN106190921A (en) | A kind of corynebacterium glutamicum and application | |
| CN102634504A (en) | Induction and stabilization of enzymatic activity in microorganisms | |
| CN109468259B (en) | Culture medium for promoting spore generation | |
| CN112961845B (en) | Method for improving fermentation level of glutamine transaminase by knocking out cslA gene | |
| WO2001005997A9 (en) | Method for production of tetanus toxin using media substantially free of animal products | |
| CN113755380A (en) | Strain culture medium for fermentation production of diphtheria toxin CRM197 protein, preparation method and strain recovery culture method | |
| CN108865931B (en) | Bacillus and application thereof | |
| CN102796680B (en) | A kind of Streptomyces roseosporus and its method for producing Daptomycin using precursor is combined | |
| CN104388367B (en) | A kind of fermentation medium of dibutyl phthalate degradation bacterium | |
| CN107267411B (en) | Glutamic acid-independent producing strain for producing gamma-polyglutamic acid by high-temperature fermentation and fermentation method thereof | |
| CN101974452A (en) | Colimycin high-yield strain and screening method thereof | |
| CN105420153B (en) | A kind of Pseudomonas aeruginosa fermentation medium and its fermentation culture method, vaccine preparation method | |
| CN113930356B (en) | Freeze-drying method for fermentation production of diphtheria toxin non-toxic CRM197 protein strain | |
| CN104740627B (en) | A kind of large-scale method for producing of pseudo- mad dog attenuated live vaccines for animals | |
| CN113604390A (en) | Corynebacterium glutamicum and application thereof in fermentation production of L-ornithine | |
| CN109652344A (en) | Bacterial strain and its application and vaccine and preparation method thereof | |
| CN114717135B (en) | Streptomyces pratensis and method for producing pseudouridine and 1-methyl-pseudouridine by fermentation of Streptomyces pratensis | |
| CN103409350A (en) | Method for culturing neisseriaceae by using hemin instead of sheep blood | |
| CA2364579A1 (en) | Culture of mycobacteria | |
| CN116590203B (en) | Corynebacterium glutamicum and application thereof in fermentation production of L-isoleucine | |
| CN102492659A (en) | Production method for hepatitis A virus for vaccine production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211207 |
|
| RJ01 | Rejection of invention patent application after publication |